of men presenting with SUI symptoms after RP prior to treatment. Men complaining only of UUI symptoms on history also predicts for DOI on UDS. UDS may be helpful in this patient group to further guide treatment decisions if initial treatment fails and to rule out SUI. Most men with MUI symptoms will have SUI identified on UDS.
INTRODUCTION AND OBJECTIVES: Sacral neuromodulation (SNM) is an effective therapy for non-obstructive urinary retention, refractory urgency/frequency and urgency incontinence, however it may be underutilized in men. There is a dearth of literature on SNM in men, as most male lower urinary tract symptoms (LUTS) research focuses on medical therapy and bladder outlet procedures, offering little guidance about SNM in men. To what extent UDS can yield diagnostic clarity in male LUTS and its role in predicting SNM success in men is unknown. Herein, we analyze how UDS findings relate to SNS utilization in men.
METHODS: A retrospective review of men undergoing SNM procedures from 2011-2015 at our institution was performed. Demographics, comorbidities, prior urologic treatments, SNM indication, and SNM utilization were assessed. Patients were stratified according to UDS 12 months before SNM (+UDS) vs. no UDS testing (-UDS). Descriptive statistics characterized the groups, T-test or chi-square tests were used where appropriate, and logistic regression was used to identify clinical and UDS parameters related to SNM outcomes.
RESULTS: 56 men underwent SNM therapy and 28 had UDS within the prior year. UDS+ and UDS-men were similar in age and co-morbid conditions. On average, +UDS men had a greater BMI (30.4+6.5 v 27.3+4.6, p 0.045). Rates of prior transurethral prostate procedures were not significantly different (17.9% v 25%) between the groups. Most (N¼53) men underwent staged implant, though 3 (+UDS N¼2, -UDS N¼1) had peripheral nerve evaluation (PNE). All PNE trials were successful, while rates of Stage 1 success (80.8% v 63.0%, p 0.22) and Stage 2 completion (95.2% v 94.1%, p 1.00) did not differ between +UDS or -UDS men. Device revision (21.4% vs. 25%, p 0.75) and explant (17.9% v 14.5%, p 1.00) rates also did not differ by +UDS or -UDS. No stress urinary incontinence (N¼0) was noted on UDS in any patient, but detrusor overactivity was present in 50% (N¼14) with urgency urinary incontinence in 25% (N¼7). UDS findings of obstruction (N¼1), poor compliance (N¼1), and hypocontracility (N¼1) were rare. Rates of Stage 1 success, Stage 2 completion, device revision, and device explant did not differ in the presence or absence of UDS-proven pathology CONCLUSIONS: Sacral nerve stimulation is a feasible treatment for men with refractory lower urinary tract symptoms. Neither the performance of urodynamics nor the presence of urodynamically-proven pathology was associated with greater likelihood of progression to stage 2, device revision or explant. Our findings suggest that SNM may be safely and effectively utilized in men without preoperative urodynamics.
Source of Funding: None

MP63-20 SYMPTOMATIC URINARY TRACT INFECTIONS' RATE POST-URODYNAMIC STUDIES AND RISK FACTORS
Michael Vainrib*, KFAR SABA, Israel INTRODUCTION AND OBJECTIVES: Urodynamic study (UDS) is an invasive ambulatory procedure that carries a risk for urinary tract infection (UTI). AUA statement justifies antimicrobial prophylaxis before UDS only in patients with certain risk factors based on studies that used a rate of all types of bacteriuria as a measure of post-UDS UTI. The aim of the study was to verify a symptomatic post-UDS UTI rate and identify possible risk factors for post-UDS symptomatic UTI.
METHODS: 398 patients in an IRB-approved retrospective review of UDS clinic electronic charts' database. Anyone with symptoms of: dysuria, urinary frequency, urgency or fever and a positive urine culture within 15 days after UDS considered as post-UDS symptomatic UTI. Following variables: age >70, male gender, past or current smoking, diabetes mellitus, neuropathic pathologies, indwelling or intermittent catheters, time interval between urine culture (UC) and a day of UDS, presence of asymptomatic bacteriuria pre-UDS were verified as possible risk factors for post-UDS UTI.
RESULTS: Mean age of a study population was 65.7 (range¼19-95) years old. 243/398(61.1%) were male. 320(80.4%) patients had a negative UC prior to UDS with a significantly lower symptomatic UTI rate of 5% compared to 14.7% symptomatic UTI rate among patients who had prior to UDS appropriately treated positive UC (p<0.02). There was no significant difference in a time interval between UC and a date of UDS in a group that developed UTI compared to an asymptomatic group (p¼0.1). In a univariate analysis, age >70, appropriately treated UC before UDS, time interval between UC and UDS more than a week, male gender, diabetes mellitus and neuropathic conditions were found as a significant variables predicting post-UDS symptomatic UTI (p<0.0001). However, in a multivariate analyses, only an appropriately treated positive UC before UDS (OR¼2.75, 95%CI¼1.04-7.27, p¼0.04) and an interval of more than a week between pre-UDS UC and UDS (OR¼2.83, 95%CI¼1.16-6.91, p¼0.022) were found as significant variables predicting symptomatic post-UDS UTI.
CONCLUSIONS: The first study to verify a symptomatic post-UDS UTI rate and identify possible risk factors for post-UDS symptomatic UTI. This study supports our antimicrobial prophylaxis protocol before UDS to minimize post-UDS UTI rate. However, a retrospective design and a relatively small number of patients in each group of proposed risk factors might cause that only few risk factors were with significance were found in a multivariate analysis. Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e843
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